The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

BACKGROUND: The incidence, risk factors, time course, and impact on survival of venous thromboembolism (VTE) in a large, population-based study of patients with bladder cancer have not been identified previously. METHODS: The California Cancer Registry was merged with the California Patient Discharge Data Set to determine the incidence of VTE in patients with newly diagnosed bladder cancer within a 6-year period. Cox proportional hazards models were used to determine the risk factors for VTE and the effects of VTE on survival. RESULTS: Among 24,861 patients with bladder cancer, the 2-year incidence of VTE was 1.9%. The highest incidence of VTE occurred in the first 6 months regardless of age, sex, race, tumor stage, or histologic subtype. In a multivariate model, significant risk factors for the development of VTE included major surgery, advancing disease stage, and increasing number of comorbidities. Compared with the general population, the 1-year standardized incidence ratio for VTE in the bladder cancer cohort was 5.3 (95% confidence interval, 4.8-5.9). Among patients with bladder cancer, significant risk factors for death included advancing disease stage, increasing comorbidities, African-American race, nontransitional cell carcinoma histology, and the development of VTE. CONCLUSIONS: Patients with bladder cancer had a 1.9% 2-year incidence of VTE. Metastatic disease was the strongest predictor of both VTE and death. It was noteworthy that cancer-associated surgery was associated with a higher risk of VTE, which differed from the results reported from other studies in solid tumors. VTE was a significant predictor of death in the first 2 years.

Original languageEnglish (US)
Pages (from-to)2596-2603
Number of pages8
JournalCancer
Volume116
Issue number11
DOIs
StatePublished - Jun 1 2010

Fingerprint

Venous Thromboembolism
Urinary Bladder Neoplasms
Survival
Incidence
Comorbidity
Neoplasms
Patient Discharge
Proportional Hazards Models
African Americans
Population
Registries
Histology

Keywords

  • Anticoagulation
  • Bladder cancer
  • Epidemiology
  • Incidence
  • Outcomes
  • Stage
  • Thromboembolism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. / Sandhu, Rasanamar; Pan, Chong-Xian; Wun, Theodore; Harvey, Danielle J; Zhou, Hong; White, Richard H; Chew, Helen K.

In: Cancer, Vol. 116, No. 11, 01.06.2010, p. 2596-2603.

Research output: Contribution to journalArticle

@article{f7b8c738483343ffb6036dcdf221de81,
title = "The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer",
abstract = "BACKGROUND: The incidence, risk factors, time course, and impact on survival of venous thromboembolism (VTE) in a large, population-based study of patients with bladder cancer have not been identified previously. METHODS: The California Cancer Registry was merged with the California Patient Discharge Data Set to determine the incidence of VTE in patients with newly diagnosed bladder cancer within a 6-year period. Cox proportional hazards models were used to determine the risk factors for VTE and the effects of VTE on survival. RESULTS: Among 24,861 patients with bladder cancer, the 2-year incidence of VTE was 1.9{\%}. The highest incidence of VTE occurred in the first 6 months regardless of age, sex, race, tumor stage, or histologic subtype. In a multivariate model, significant risk factors for the development of VTE included major surgery, advancing disease stage, and increasing number of comorbidities. Compared with the general population, the 1-year standardized incidence ratio for VTE in the bladder cancer cohort was 5.3 (95{\%} confidence interval, 4.8-5.9). Among patients with bladder cancer, significant risk factors for death included advancing disease stage, increasing comorbidities, African-American race, nontransitional cell carcinoma histology, and the development of VTE. CONCLUSIONS: Patients with bladder cancer had a 1.9{\%} 2-year incidence of VTE. Metastatic disease was the strongest predictor of both VTE and death. It was noteworthy that cancer-associated surgery was associated with a higher risk of VTE, which differed from the results reported from other studies in solid tumors. VTE was a significant predictor of death in the first 2 years.",
keywords = "Anticoagulation, Bladder cancer, Epidemiology, Incidence, Outcomes, Stage, Thromboembolism",
author = "Rasanamar Sandhu and Chong-Xian Pan and Theodore Wun and Harvey, {Danielle J} and Hong Zhou and White, {Richard H} and Chew, {Helen K}",
year = "2010",
month = "6",
day = "1",
doi = "10.1002/cncr.25004",
language = "English (US)",
volume = "116",
pages = "2596--2603",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer

AU - Sandhu, Rasanamar

AU - Pan, Chong-Xian

AU - Wun, Theodore

AU - Harvey, Danielle J

AU - Zhou, Hong

AU - White, Richard H

AU - Chew, Helen K

PY - 2010/6/1

Y1 - 2010/6/1

N2 - BACKGROUND: The incidence, risk factors, time course, and impact on survival of venous thromboembolism (VTE) in a large, population-based study of patients with bladder cancer have not been identified previously. METHODS: The California Cancer Registry was merged with the California Patient Discharge Data Set to determine the incidence of VTE in patients with newly diagnosed bladder cancer within a 6-year period. Cox proportional hazards models were used to determine the risk factors for VTE and the effects of VTE on survival. RESULTS: Among 24,861 patients with bladder cancer, the 2-year incidence of VTE was 1.9%. The highest incidence of VTE occurred in the first 6 months regardless of age, sex, race, tumor stage, or histologic subtype. In a multivariate model, significant risk factors for the development of VTE included major surgery, advancing disease stage, and increasing number of comorbidities. Compared with the general population, the 1-year standardized incidence ratio for VTE in the bladder cancer cohort was 5.3 (95% confidence interval, 4.8-5.9). Among patients with bladder cancer, significant risk factors for death included advancing disease stage, increasing comorbidities, African-American race, nontransitional cell carcinoma histology, and the development of VTE. CONCLUSIONS: Patients with bladder cancer had a 1.9% 2-year incidence of VTE. Metastatic disease was the strongest predictor of both VTE and death. It was noteworthy that cancer-associated surgery was associated with a higher risk of VTE, which differed from the results reported from other studies in solid tumors. VTE was a significant predictor of death in the first 2 years.

AB - BACKGROUND: The incidence, risk factors, time course, and impact on survival of venous thromboembolism (VTE) in a large, population-based study of patients with bladder cancer have not been identified previously. METHODS: The California Cancer Registry was merged with the California Patient Discharge Data Set to determine the incidence of VTE in patients with newly diagnosed bladder cancer within a 6-year period. Cox proportional hazards models were used to determine the risk factors for VTE and the effects of VTE on survival. RESULTS: Among 24,861 patients with bladder cancer, the 2-year incidence of VTE was 1.9%. The highest incidence of VTE occurred in the first 6 months regardless of age, sex, race, tumor stage, or histologic subtype. In a multivariate model, significant risk factors for the development of VTE included major surgery, advancing disease stage, and increasing number of comorbidities. Compared with the general population, the 1-year standardized incidence ratio for VTE in the bladder cancer cohort was 5.3 (95% confidence interval, 4.8-5.9). Among patients with bladder cancer, significant risk factors for death included advancing disease stage, increasing comorbidities, African-American race, nontransitional cell carcinoma histology, and the development of VTE. CONCLUSIONS: Patients with bladder cancer had a 1.9% 2-year incidence of VTE. Metastatic disease was the strongest predictor of both VTE and death. It was noteworthy that cancer-associated surgery was associated with a higher risk of VTE, which differed from the results reported from other studies in solid tumors. VTE was a significant predictor of death in the first 2 years.

KW - Anticoagulation

KW - Bladder cancer

KW - Epidemiology

KW - Incidence

KW - Outcomes

KW - Stage

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=77952807952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952807952&partnerID=8YFLogxK

U2 - 10.1002/cncr.25004

DO - 10.1002/cncr.25004

M3 - Article

C2 - 20336780

AN - SCOPUS:77952807952

VL - 116

SP - 2596

EP - 2603

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -